Literature DB >> 14573971

Long-term results of transscleral cyclophotocoagulation in refractory pediatric glaucoma patients.

R Autrata1, J Rehurek.   

Abstract

We evaluated efficacy and complications of diode laser cyclophotocoagulation in pediatric patients with refractory glaucomas. The retrospective study comprised 69 eyes of 53 pediatric patients with uncontrolled refractory glaucoma treated by transscleral diode laser cyclophotocoagulation. The mean age was 6.1 +/- 4.29 (range 0.9-15) years. The main parameters evaluated were: intraocular pressure (IOP), visual acuity, and complications. The mean follow-up period was 5.6 +/- 2.8 (range 2.2-9.5) years. Treatment success was defined as a postoperative IOP of </=21 mm Hg, with or without adjunctive glaucoma medications. The baseline mean pretreatment IOP was 34.08 +/- 7.13 (range 24-47) mm Hg. The final mean postoperative IOP was 20.81 +/- 6.38 (range 12-33) mm Hg after a mean of 2.13 +/- 1.47 (range 1-6) laser procedures. After one treatment session, 66% of the eyes had a successful reduction in IOP (</=21 mm Hg), but this had fallen to 41% by 1 year. With repeat cyclophotocoagulation, 79% of the eyes had a clinically effective reduction in IOP(</=21 mm Hg) for 1 year (mean 7.1-month interval between treatments). Postoperative complications included choroidal detachment in 4 eyes and retinal detachment in 2 eyes with progression of vision loss. All these complications occurred in aphakic patients. Cyclophotocoagulation by diode laser is a useful therapy for the treatment of refractory pediatric glaucomas with uncontrolled IOP. Cyclodiode repeated treatment can provide effective control of IOP with a low risk of severe complications. Aphakic patients may have an increased risk of postoperative complications. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2003        PMID: 14573971     DOI: 10.1159/000073068

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  10 in total

1.  Cyclodiode treatment of neovascular glaucoma secondary to Coats' disease.

Authors:  D J de Silva; J L Brookes
Journal:  Br J Ophthalmol       Date:  2007-05       Impact factor: 4.638

2.  Baerveldt glaucoma implant in paediatric patients.

Authors:  K A van Overdam; J T H N de Faber; H G Lemij; P W T de Waard
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

3.  [Glaucoma surgery in children].

Authors:  T S Dietlein
Journal:  Ophthalmologe       Date:  2015-02       Impact factor: 1.059

Review 4.  Congenital and infantile cataract: aetiology and management.

Authors:  Wai H Chan; Susmito Biswas; Jane L Ashworth; I Christopher Lloyd
Journal:  Eur J Pediatr       Date:  2012-03-01       Impact factor: 3.183

Review 5.  Childhood glaucoma surgery in the 21st century.

Authors:  M Papadopoulos; B Edmunds; C Fenerty; P T Khaw
Journal:  Eye (Lond)       Date:  2014-06-13       Impact factor: 3.775

6.  Transscleral diode laser cyclophotocoagulation as primary surgical treatment for secondary glaucoma in juvenile idiopathic arthritis: high failure rate after short term follow up.

Authors:  C Heinz; J M Koch; A Heiligenhaus
Journal:  Br J Ophthalmol       Date:  2006-06       Impact factor: 4.638

Review 7.  Lasers in Glaucoma: an Overview.

Authors:  Bhawesh Chandra Saha; Rashmi Kumari; Bibhuti Prasanna Sinha; Anita Ambasta; Sanjeev Kumar
Journal:  Int Ophthalmol       Date:  2020-11-19       Impact factor: 2.031

8.  Advanced glaucoma following Nd:YAG capsulotomy: a case report.

Authors:  Colin Goudie; Andrew Tatham
Journal:  BMC Ophthalmol       Date:  2018-09-14       Impact factor: 2.209

Review 9.  Lasers in glaucoma.

Authors:  Harsh Kumar; Tarannum Mansoori; Gazella B Warjri; Bindu I Somarajan; Suman Bandil; Viney Gupta
Journal:  Indian J Ophthalmol       Date:  2018-11       Impact factor: 1.848

10.  Current surgical options for the management of pediatric glaucoma.

Authors:  Jose Morales; Sami Al Shahwan; Sami Al Odhayb; Ibrahim Al Jadaan; Deepak P Edward
Journal:  J Ophthalmol       Date:  2013-04-24       Impact factor: 1.909

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.